AEZS Related Analyst Ratings

Jan 3, 2013 08:00 AM MLV & Co. Upgrades Æterna Zentaris (AEZS) to Buy

Sep 20, 2012 07:04 AM Roth Capital Starts Æterna Zentaris (AEZS) at Buy

Aug 16, 2012 01:23 PM Oppenheimer Maintains a 'Perform' on Æterna Zentaris (AEZS) as Outlook Doesn't Seem to Improve

Apr 3, 2012 10:34 AM Summer Street Downgrades Æterna Zentaris (AEZS) to Neutral

Apr 3, 2012 07:56 AM Rodman & Renshaw Downgrades Æterna Zentaris (AEZS) to Market Perform

Apr 3, 2012 07:52 AM Desjardins Downgrades Æterna Zentaris (AEZS) to Hold

Apr 2, 2012 01:42 PM Oppenheimer Cuts Æterna Zentaris (AEZS) to Perform

Apr 2, 2012 01:40 PM Canaccord Genuity Downgrades Æterna Zentaris (AEZS) to Hold

Apr 2, 2012 12:40 PM McNicoll Lewis & Vlak Cuts Æterna Zentaris (AEZS) to Hold

Aug 12, 2011 07:32 AM Needham & Company Reiterates a 'Buy' on Æterna Zentaris (AEZS); Busy Summer Brings Completion of Perifosine and AEZS-108 Pivotal Trials

Aug 9, 2011 02:06 PM Desjardins Upgrades AEterna Zentaris (AEZS) to Buy, Reaffirms Price Target

Jul 12, 2011 03:35 PM Needham & Company reiterates a 'Buy' on Æterna Zentaris (AEZS); Newly Issued Use Patent Provides L-T Protection for Perifosine in the EU

Jun 27, 2011 07:37 AM Needham & Company Maintains a'Buy' on Æterna Zentaris (AEZS); Discussion with Management

Jun 7, 2011 07:52 AM Oppenheimer Starts Æterna Zentaris (AEZS) at Outperform

May 31, 2011 07:50 AM Needham & Company Starts �terna Zentaris (AEZS) at Buy; Three Late-Stage Trials, Three Partners, and Three Potential Stock Catalysts

May 4, 2011 11:02 AM Summer Street Starts Æterna Zentaris (AEZS) at Buy

Apr 27, 2011 01:01 PM Canaccord Genuity Reiterates a 'Speculative Buy' on Æterna Zentaris (AEZS); Adding to Canadian Focus List

Mar 23, 2011 11:08 AM Canaccord Genuity Maintains a 'Speculative Buy' on Æterna Zentaris (AEZS); Q4 Results: Delay for Phase III Multiple Myeloma Trial, but CRC Remains on Track

Mar 16, 2011 07:44 AM JMP Starts Keryx (KERX), AEterna Zentaris (AEZS) at Outperform

Dec 20, 2010 10:51 AM Canaccord Genuity Maintains a 'Speculative Buy' Æterna Zentaris (AEZS); Analyst and Investor Day: Highlighting a Deep Pipeline

Nov 29, 2010 11:54 AM McNicoll Lewis & Vlak Starts Æterna Zentaris (AEZS) at Buy; Sales Revenue and Funded Phase III Trials Support Perifosine Development

Aug 16, 2010 10:52 AM Canaccord Genuity Maintains a 'Speculative Buy' Rating on AEterna Zentaris (AEZS); Next Catalyst

Jun 8, 2010 11:36 AM Canaccord Genuity Keeps 'Speculative Buy' Rating on AEterna Zentaris (AEZS) After AEZS-108 and Perifosine Data Presented at ASCO

Apr 5, 2010 03:18 PM Canaccord Adams Maintains a 'Speculative Buy'on AEterna Zentaris (AEZS); Positive FDA Data From Partner Keryx Pharmaceuticals (KERX)

Aug 18, 2009 11:01 AM Canaccord Adams Downgrades AEterna Zentaris (AEZS) to Speculative Buy; Negative Phase III Study Results

Apr 23, 2008 08:19 AM Dundee Downgrades AEterna Zentaris (AEZS) to Neutral

May 15, 2007 08:30 AM Opeenheimer Starts AEterna Zentaris (AEZS) at Buy

Oct 27, 2006 07:47 AM CIBC Starts AEterna Zentaris (AEZS) at Sector Outperform

May 16, 2006 10:10 AM GMP Securities Initiates Coverage on Aeterna Zentaris (AEZS)

May 4, 2006 10:43 AM Rodman & Renshaw Raises Price Target on AEterna Zentaris (AEZS)

Aug 3, 2005 09:49 AM Rodman & Renshaw Starts AEZS at Market Outperform